Off-label uses of monoclonal antibodies for treatment of B-cell lymphoid or myeloid malignancies

BlueCross BlueShield Association
Record ID 32003000735
Authors' objectives:

The objectives of this Assessment are to review the available evidence on off-label uses of the three approved monoclonal antibodies - rituximab, gemtuzumab ozogamicin and alemtuzumab for the treatment of B-cell lymphoid or myeloid malignancies.

Authors' methods: Systematic review
Project Status: Completed
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Antibodies, Monoclonal
  • Leukemia, Myeloid
  • Lymphoma, B-Cell
Organisation Name: BlueCross BlueShield Association
Contact Address: BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name:
Contact Email:
Copyright: BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.